Bristol Myers Squibb (2023) Inrebic® (fedratinib) prescribing information. https://packageinserts.bms.com/pi/pi_inrebic.pdf. Accessed 20 Mar 2024

European Medicines Agency Inrebic® (fedratinib) [summary of product characteristics]. Dublin, Ireland: Bristol Myers Squibb (2024) https://www.ema.europa.eu/en/documents/product-information/inrebic-epar-product-information_en.pdf. Accessed 20 Mar 2024

Pardanani A, Gotlib JR, Jamieson C, Cortes JE, Talpaz M, Stone RM, Silverman MH, Gilliland DG, Shorr J, Tefferi A (2011) Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol 29(7):789–796. https://doi.org/10.1200/JCO.2010.32.8021

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pardanani A, Tefferi A, Jamieson C, Gabrail NY, Lebedinsky C, Gao G, Liu F, Xu C, Cao H, Talpaz M (2015) A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis. Blood Cancer J 5(8):e335. https://doi.org/10.1038/bcj.2015.63

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ogasawara K, Zhou S, Krishna G, Palmisano M, Li Y (2019) Population pharmacokinetics of fedratinib in patients with myelofibrosis, polycythemia vera, and essential thrombocythemia. Cancer Chemother Pharmacol 84(4):891–898. https://doi.org/10.1007/s00280-019-03929-9

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang M, Xu C, Ma L, Shamiyeh E, Yin J, von Moltke LL, Smith WB (2015) Effect of food on the bioavailability and tolerability of the JAK2-selective inhibitor fedratinib (SAR302503): results from two phase I studies in healthy volunteers. Clin Pharmacol Drug Dev 4(4):315–321. https://doi.org/10.1002/cpdd.161

Article  CAS  PubMed  Google Scholar 

Zhang M, Xu CR, Shamiyeh E, Liu F, Yin JY, von Moltke LL, Smith WB (2014) A randomized, placebo-controlled study of the pharmacokinetics, pharmacodynamics, and tolerability of the oral JAK2 inhibitor fedratinib (SAR302503) in healthy volunteers. J Clin Pharmacol 54(4):415–421. https://doi.org/10.1002/jcph.218

Article  CAS  PubMed  Google Scholar 

Ogasawara K, Xu C, Kanamaluru V, Siebers N, Surapaneni S, Ridoux L, Palmisano M, Krishna G (2020) Excretion balance and pharmacokinetics following a single oral dose of [(14)C]-fedratinib in healthy subjects. Cancer Chemother Pharmacol 86(2):307–314. https://doi.org/10.1007/s00280-020-04121-0

Article  CAS  PubMed  Google Scholar 

Wu F, Krishna G, Surapaneni S (2020) Physiologically based pharmacokinetic modeling to assess metabolic drug-drug interaction risks and inform the drug label for fedratinib. Cancer Chemother Pharmacol 86(4):461–473. https://doi.org/10.1007/s00280-020-04131-y

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jean D, Naik K, Milligan L, Hall S, Mei Huang S, Isoherranen N, Kuemmel C, Seo P, Tegenge MA, Wang Y, Yang Y, Zhang X, Zhao L, Zhao P, Benjamin J, Bergman K, Grillo J, Madabushi R, Wu F, Zhu H, Zineh I (2021) Development of best practices in physiologically based pharmacokinetic modeling to support clinical pharmacology regulatory decision-making-A workshop summary. CPT Pharmacometrics Syst Pharmacol 10(11):1271–1275. https://doi.org/10.1002/psp4.12706

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jones HM, Chen Y, Gibson C, Heimbach T, Parrott N, Peters SA, Snoeys J, Upreti VV, Zheng M, Hall SD (2015) Physiologically based pharmacokinetic modeling in drug discovery and development: a pharmaceutical industry perspective. Clin Pharmacol Ther 97(3):247–262. https://doi.org/10.1002/cpt.37

Article  CAS  PubMed  Google Scholar 

Zhang X, Yang Y, Grimstein M, Fan J, Grillo JA, Huang SM, Zhu H, Wang Y (2020) Application of PBPK modeling and simulation for regulatory decision making and its impact on US prescribing information: an update on the 2018–2019 submissions to the US FDA’s Office of Clinical Pharmacology. J Clin Pharmacol 60(Suppl 1):S160–s178. https://doi.org/10.1002/jcph.1767

Article  CAS  PubMed  Google Scholar 

Ogasawara K, Xu C, Kanamaluru V, Palmisano M, Krishna G (2020) Effects of repeated oral doses of ketoconazole on a sequential ascending single oral dose of fedratinib in healthy subjects. Cancer Chemother Pharmacol 85(5):899–906. https://doi.org/10.1007/s00280-020-04067-3

Article  CAS  PubMed  Google Scholar 

Chen Y, Ogasawara K, Wood-Horrall R, Thomas M, Thomas M, He B, Liu L, Xue Y, Surapaneni S, Carayannopoulos LN, Zhou S, Palmisano M, Krishna G (2022) Effect of fluconazole on the pharmacokinetics of a single dose of fedratinib in healthy adults. Cancer Chemother Pharmacol 90(4):325–334. https://doi.org/10.1007/s00280-022-04464-w

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ogasawara K, Vince B, Xu C, Zhang M, Palmisano M, Krishna G (2020) A phase I study of the effect of repeated oral doses of pantoprazole on the pharmacokinetics of a single dose of fedratinib in healthy male subjects. Cancer Chemother Pharmacol 85(5):995–1001. https://doi.org/10.1007/s00280-020-04074-4

Article  CAS  PubMed  Google Scholar 

Ogasawara K, LoRusso PM, Olszanski AJ, Rixe O, Xu C, Yin J, Palmisano M, Krishna G (2020) Assessment of effects of repeated oral doses of fedratinib on inhibition of cytochrome P450 activities in patients with solid tumors using a cocktail approach. Cancer Chemother Pharmacol 86(1):87–95. https://doi.org/10.1007/s00280-020-04102-3

Article  CAS  PubMed  Google Scholar 

Simcyp (2021) V19R1_V20R1_VersionComparison. Simcyp Resource

Almond LM, Mukadam S, Gardner I, Okialda K, Wong S, Hatley O, Tay S, Rowland-Yeo K, Jamei M, Rostami-Hodjegan A, Kenny JR (2016) Prediction of drug-drug interactions arising from CYP3A induction using a physiologically based dynamic model. Drug Metab Dispos 44(6):821–832. https://doi.org/10.1124/dmd.115.066845

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rowland Yeo K, Jamei M, Yang J, Tucker GT, Rostami-Hodjegan A (2010) Physiologically based mechanistic modelling to predict complex drug-drug interactions involving simultaneous competitive and time-dependent enzyme inhibition by parent compound and its metabolite in both liver and gut - the effect of diltiazem on the time-course of exposure to triazolam. Eur J Pharm Sci 39(5):298–309. https://doi.org/10.1016/j.ejps.2009.12.002

Article  CAS  PubMed  Google Scholar 

Yeo KR, Jamei M, Rostami-Hodjegan A (2013) Predicting drug-drug interactions: application of physiologically based pharmacokinetic models under a systems biology approach. Expert Rev Clin Pharmacol 6(2):143–157. https://doi.org/10.1586/ecp.13.4

Article  CAS  PubMed  Google Scholar 

Ogasawara K, Kam J, Thomas M, Liu L, Liu M, Xue Y, Surapaneni S, Carayannopoulos LN, Zhou S, Palmisano M, Krishna G (2021) Effects of strong and moderate CYP3A4 inducers on the pharmacokinetics of fedratinib in healthy adult participants. Cancer Chemother Pharmacol 88(3):369–377. https://doi.org/10.1007/s00280-021-04292-4

Article  CAS  PubMed  Google Scholar